Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent
A diagnosis of T2DM of ≥6 months,
Hemoglobin A1c (HbA1c) ≥6.5% to ≤10% at Screening
Have a BMI ≥27.0 kg/m2
You may not be if
Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. All participants must have a photo fundoscopy, optical coherence tomography, or slit lamp assessment prior to randomization and within the last 12 months to confirm the absence or stable status of diabetic retinopathy and/or macular edema.
Present or planned use of any drug that could interfere with glucose levels
Self-reported change in body weight \>5 kg (11 pounds) within 3 months before screening
Have prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to Screening)
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening, including, but not limited to, mucosal ablation, gastric artery embolization, intragastric balloon, and duodenal-jejunal endoluminal liner
Clareo Health | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
